Cormorant Asset Management, LP Immunovant, Inc. Transaction History

Cormorant Asset Management, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$31.31 - $44.19 $1.88 Million - $2.65 Million	-60,000 Reduced 4.9%	1,165,000 $49.1 Million
Q3 2023 Nov 14, 2023	BUY	$18.55 - $39.96 $12.5 Million - $27 Million	675,000 Added 122.73%	1,225,000 $47 Million
Q2 2023 Aug 14, 2023	BUY	$14.2 - $23.75 $7.81 Million - $13.1 Million	550,000 New	550,000 $10.4 Million
Q4 2022 Feb 14, 2023	BUY	$6.59 - $17.75 $2.64 Million - $7.1 Million	400,000 New	400,000 $7.1 Million
Q2 2021 Aug 16, 2021	SELL	$9.4 - $16.85 $3.17 Million - $5.68 Million	-337,048 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$13.08 - $49.6 $16 Million - $60.8 Million	-1,225,904 Reduced 78.44%	337,048 $5.41 Million
Q4 2020 Feb 16, 2021	SELL	$36.36 - $52.71 $2.73 Million - $3.95 Million	-74,999 Reduced 4.58%	1,562,952 $72.2 Million
Q3 2020 Nov 16, 2020	BUY	$22.61 - $38.9 $37 Million - $63.7 Million	1,637,951 New	1,637,951 $57.6 Million

211

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.